Drug Approval | November 21, 2022
Aurobindo Pharma receives 10 observations for Unit IX
The company had responded to the agency and carried out the required corrective actions.
The company had responded to the agency and carried out the required corrective actions.
The product is expected to be launched by Q4 FY23.
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The company is focussed on increasing the capacity utilizations while controlling costs
The company sees the business reaching $100mn
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
Subscribe To Our Newsletter & Stay Updated
